Medication info
Rinatigen Duo Extended-Release Tablets 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Rinatigen Duo Extended-Release Tablets 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
N BK Pharmaceutical Co., Ltd.
Appearance
Yellow oval extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202400661 · Approved 2024.03.26 · Insurance code 652607320

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 5/1000 mg extended-release tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored, and the dose should be adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
N BK Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to assist patients with type 2 diabetes in achieving more effective blood sugar control by complementing dietary and exercise therapy. It is particularly suitable for patients requiring combination therapy with linagliptin and metformin, helping to manage blood sugar levels stably. This way, it supports enhanced diabetes management and helps maintain a healthy lifestyle.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 5/1000 mg extended-release tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored, and the dose should be adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication is used for the treatment of type 2 diabetes and helps in controlling blood sugar levels. However, precautions must be strictly followed while taking this medication. First, this medication can rarely cause a serious condition known as lactic acidosis, which can lead to the excessive accumulation of lactic acid in the body, posing a dangerous condition requiring immediate treatment. Therefore, patients with moderate to severe kidney impairment, acute kidney injury, severe infections, or significant dehydration should not take this medication. Additionally, it is safer for patients with liver dysfunction, acute alcohol intoxication, or serious heart or respiratory diseases not to use this medication. Hypoglycemic symptoms may occur during the course of this medication, so care should be taken to monitor blood sugar changes, especially when taken with sulfonylureas or insulin. Acute pancreatitis or blistering skin diseases may also arise, so if severe abdominal pain or skin abnormalities occur during use, immediate consultation with a physician is necessary. This medication can lower vitamin B12 levels, so during long-term use, it is necessary to confirm vitamin B12 status through a blood test. Swallow the tablets whole without crushing, chewing, or breaking them, and it is normal for the tablet shell to pass in the stool. Furthermore, this medication may interact with other drugs, so if other medications are being taken, it is essential to inform your doctor or pharmacist. Women who are pregnant or breastfeeding should avoid this medication, and those planning a pregnancy should consult a doctor. Elderly patients may have decreased kidney function, so regular kidney function tests should be conducted, and dosage adjustments may be necessary. Finally, in case of overdose, immediate medical attention should be sought for appropriate treatment, and prompt action is needed, especially when symptoms of lactic acidosis occur. By adhering to these precautions and following the doctor’s instructions, the benefits of this medication can be safely enjoyed.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • nasopharyngitis
  • hypersensitivity reactions
  • angioedema
  • urticaria
  • lactic acidosis
  • abnormal vitamin B12 absorption test
  • hypoglycemic syndrome
  • taste disturbances
Show 136 more
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulceration
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • dermatitis herpetiformis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • renal transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • palpitations
  • dry eyes
  • glaucoma
  • cataract
  • eye discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • nausea
  • gastroesophageal reflux disease
  • gastritis
  • dizziness
  • sensory loss
  • chest discomfort
  • asthenia
  • pain
  • epistaxis
  • oropharyngeal pain
  • voice disorders
  • allergic rhinitis
  • exertional dyspnea
  • wet cough
  • rhinorrhea
  • pulmonary mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • increased serum triglycerides
  • increased urine albumin/creatinine ratio
  • positive urine leukocytes
  • hemoglobin reduction
  • increased serum potassium
  • increased serum creatinine
  • increased serum creatine kinase activity
  • increased ALT
  • increased AST
  • androgenetic alopecia
  • hyperhidrosis
  • dermatitis
  • anxiety
  • confusion
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Yellow oval extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.